Friday 14th May 2021
Can you imagine a world where we could have a greater understanding of Raynaud’s? Have more information on what triggers an attack? Understand how in some cases Raynaud’s combined with other symptoms may be an early predictor of scleroderma? The Raynaud’s ResearchApp, an SRUK-led partnership with app development company Healthbit and data company D4T4, intends to do just this!
Friday 7th May 2021
SRUK is pioneering ‘The Raynaud’s ResearchApp,’ that aims to help identify Raynaud’s patients at risk of developing scleroderma, with a view to achieving earlier diagnosis and improved outcomes. The technology also enables users to record their experiences of Raynaud’s symptoms and learn more about potential triggers. The App has recently been piloted in a clinical trial.
Friday 23rd April 2021
How does our everyday diet influence how we feel, and could a few simple changes really make a difference?
Friday 16th April 2021
What is the link between our genetic code and developing scleroderma? Researchers from Spain have recently studied genetic alterations and established a connection with the pathways that dictate the clinical features of scleroderma. The study is significant because increasing our understanding of the genetic pathway could be a faster route towards identifying effective new therapies for this complex condition.
Thursday 1st April 2021
SRUK is working with our partners at the Association of Medical Research Charities via their new Open Research Platform, to revolutionise the publishing process for our researchers. This will enable SRUK-funded research groups to publish their work in a streamlined and cost-effective way, with the ultimate goal of translating new knowledge into effective treatments for people living with scleroderma.
Friday 19th March 2021
Clinical trials are the only way to ensure that new treatments are effective. But how exactly does the process work? FInd out why 'outcome measures’ and ‘endpoints’ are crucial, and how SRUK funding is playing a key role in improving the measures used in treatments for scleroderma.
Thursday 25th February 2021
A new study from the UK has identified a possible connection between metabolism and fibrosis in people with scleroderma, with the potential to open up new treatment avenues in the future.
Wednesday 10th February 2021
Our new research reveals that nearly half of UK adults don’t know any of the signs of Raynaud’s disease despite it being as common as hay fever and affecting one-in-six people.
Thursday 21st January 2021
A member of our community has published a book! Jonathan Levitt is the author of Contemplating Comedy, which is available now. Written mainly during the first lockdown, this book is packed with humour combined with the author’s own insights, experiences and ideas, all accompanied by a collection of original cartoon illustrations
Monday 18th January 2021
Would you like to have your say on whether a treatment is made available for progressive fibrosing interstitial lung disease (PF-ILD)?
